Pyrrolotriazine kinase inhibitors
AssigneeBristol-Myers Squibb Company
InventorsMark D. Wittman, Kurt Zimmermann, Xiaopeng Sang
Life of this patent
Estimating the term…
Abstract
The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
Claims1
A method of treating a protein kinase (PK) related disorder associated with the activity of an IGF-1R kinase wherein said disorder is selected from the group consisting of carcinoma of the prostate, thyroid cancer, neuroblastoma, glioblastoma, medulloblastoma, melanoma, multiple myeloma, and acute myelogenous leukemia (AML) in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound having the formula
- or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.
Dependencies are inferred from the claim text.